NASDAQ · TTRX
Turn Therapeutics Inc.
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
Loading market information…
NASDAQ · CCLD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CareCloud, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CareCloud, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CareCloud, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CareCloud, Inc. operates as a specialized healthcare technology firm, delivering a comprehensive portfolio of cloud-powered solutions and related professional services. Its primary clientele consists of medical providers and hospitals throughout the United States. The company strategically organizes its activities into two core divisions: Healthcare IT and Medical Practice Management. Through its Software-as-a-Service (SaaS) platform, CareCloud provides essential tools for managing revenue cycles, administering practices, handling electronic health records, gleaning business insights, facilitating telehealth, and enhancing patient engagement. These offerings, complemented by various software utilities and tailored business services, are designed to empower diverse medical groups and health systems. Professionals such as doctors, nurses, physician assistants, and other clinical staff who render billable services are among its key users. Established in 1999 and based in Somerset, New Jersey, the entity was originally named MTBC, Inc. before officially adopting CareCloud, Inc. in March 2021.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 6, 2025 |
| -$0.04-157.14% vs estimate |
| $27.60M+7.59% vs estimate |
| Q4 2024 | Mar 13, 2025 | $0.00-99.29% vs estimate | $28.24M+0.9% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.04+70.71% vs estimate | $28.55M+0.04% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$2.69+$0.08 (+3.07%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 47.05% below the high.
$1.94-$0.05 (-2.51%)
Seer, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.49% below the high.
$7.36+$0.10 (+1.38%)
The Joint Corp.’s quoted price sits in the lower half of its reported 52-week range, 31.02% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
